Sleeping pills called Z-drugs work like benzodiazepines but have different molecules
In short: Z-drugs are a family of sleeping pills named because several of their names begin with Z. They act on the same brain receptors as benzodiazepines, yet their chemical structures differ. That shared mechanism explains why they bring similar benefits, side effects and risks, and why doctors limit how long they are prescribed.
Nonbenzodiazepines, often called Z-drugs after well-known members such as zopiclone, zolpidem and zaleplon, are sedative and hypnotic drugs. They work as positive allosteric modulators of the GABAA receptor at the benzodiazepine binding site. Because they act through the same mechanism as benzodiazepines, they share many of their benefits, side effects and risks, even though their molecular structures are different. The first Z-drugs appeared in the late 1980s and early 1990s. Zopiclone was approved by the British National Health Service in 1989, zolpidem followed from Sanofi, and the US Food and Drug Administration later approved zaleplon, eszopiclone and extended-release and sublingual forms of zolpidem.
They were initially thought to carry less risk of physical dependence and addiction than benzodiazepines, but these problems can still arise, and tolerance develops within days to weeks. Evidence on benefit is modest. Z-drugs shorten the time taken to fall asleep by about 10 to 20 minutes, but no Z-drug has shown a clinically significant increase in total sleep time.
Guidance recommends the lowest effective dose for two to three weeks in short-term insomnia, and use beyond four weeks is not recommended. A 2004 meta-analysis found few clear differences between zopiclone and benzodiazepines in sleep measures, adverse events or tolerance, and a 2022 review estimated that 40 to 50 percent of users experience adverse effects. The concerns are serious and still debated. Analyses of trial data submitted to the FDA found that zolpidem, zaleplon and eszopiclone more than doubled the risk of depression compared with placebo, and long-term users showed raised suicide and overall mortality risk. Older people face particular danger, with falls, hip fractures and motor vehicle accidents reported. Cognitive behavioral therapy for insomnia, by contrast, has been found to improve sleep quality for at least a year after treatment.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Nonbenzodiazepine
- Also: Clinics and practice — Primary Care Prescribing Patterns for Benzodiazepines and Z-Drugs, and Evidence Gaps Concerning Hydroxyzine and Seasonality: A Systematic Review. · CC BY
To cite this card, link to https://intellectplus.co.uk/app/health-nonbenzodiazepine.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health, medicine and disease · More in Health · Latest · A–Z · All topics